Chinese carmaker BYD unveils 5-minute EV charging
SHANGHAI, China (WTVO) — Chinese carmaker BYD has unveiled new technology that allows electric vehicles to charge to full in about 5 minutes, or the time it takes to fill a gas car.
BYD's Super e-Platform reaches charging speeds of 1,000 kilowatts at 1,000 volts, twice as powerful as the fastest chargers available in the United States.
At the Shanghai Auto Show, the company claimed its electric sedans, the Han L and the Tang L SUV, can gain 250 miles of range in as little as 5 minutes.
By comparison, a Tesla can add 167 miles of range in 15 minutes at a 350 kW Supercharger.
'We have been pursuing a goal to make the charging time of electric vehicles as short as the refuelling time of petrol vehicles,' BYD founder Wang Chuanfu said.
BYD's Super e-Platform produces vehicles built on a 1,000-volt architecture, higher than current high-end EVs that run on 800 volts. Engineers were tasked with solving 'multi-physics challenges' in vehicle design to accommodate the power.
To manage heat, BYD created an 'all liquid-cooled megawatt flash charging thermal system' for thermal management while the vehicle is charging, to protect the battery.
The Han L utilizes an 83.2 kWh battery pack, while the Tang L harnesses a 100 kWh pack, made of lithium-iron-phosphate (LFP) cells.
LFP is said to offer better longevity than the more common nickel manganese cobalt (NMC) batteries used in the West.
To accomplish fast charging, BYD created Megawatt charging stations with a maximum output of 1,360 kW. The company said 4,000 of the chargers will be rolled out in China first, before appearing in global markets.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
For the latest news, weather, sports, and streaming video, head to MyStateline | WTVO News, Weather and Sports.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
15 minutes ago
- Yahoo
Centuri Holdings (CTRI) Surged This Week. Here is Why.
The share price of Centuri Holdings, Inc. (NYSE:CTRI) surged by 9.74% between May 29 and June 5, 2025, putting it among the Energy Stocks that Gained the Most This Week. Let's shed some light on the development. A close-up of an electrical power line with a bright blue sky in the background, highlighting the company's selection of electricity and natural gas services. Centuri Holdings, Inc. (NYSE:CTRI) is a strategic utility infrastructure services company that partners with regulated utilities to build and maintain the energy network that powers millions of homes and businesses across the United States and Canada. Centuri Holdings, Inc. (NYSE:CTRI) continues to surge after the company announced $350 million in new customer awards in late May, reflecting strong demand for the company's infrastructure solutions across North America. The awards span the United States and include work supporting electric and gas infrastructure modernization, water relocation, utility distribution, and renewables. This comes after Centuri Holdings had already announced nearly $490 million in multi-year customer awards earlier this year. The share price of Centuri Holdings, Inc. (NYSE:CTRI) has gained almost 23% over the last month. While we acknowledge the potential of CTRI as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 10 Cheap Energy Stocks to Buy Now and Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
16 minutes ago
- Yahoo
Array Technologies (ARRY) Gained Over 11% This Week. Here is Why.
The share price of Array Technologies, Inc. (NASDAQ:ARRY) surged by 11.78% between May 29 and June 5, 2025, putting it among the Energy Stocks that Gained the Most This Week. Let's shed some light on the development. An aerial view of a solar panel farm, its panel incremented tracking the sun's path. Array Technologies, Inc. (NASDAQ:ARRY) is a leading global provider of solar tracking technology to utility-scale and distributed generation customers, who construct, develop, and operate solar PV sites. Array Technologies, Inc. (NASDAQ:ARRY) fell by over 20% last month after investors reacted negatively to President Trump's sweeping tax and spending bill advancing through the House of Representatives, which may result in the termination of numerous subsidies that have supported the renewable energy sector. The bill is expected to have devastating consequences for the booming solar industry, which relies heavily on such credits. So ARRY's recent rebound could be due to investors flocking in to purchase the stock at a lower, more attractive price. Moreover, it must be mentioned that Array Technologies, Inc. (NASDAQ:ARRY) posted strong results in its Q1 2025 last month, beating forecasts in both revenue and earnings. Moreover, the company achieved the second-largest quarter of volume shipped since 2023 and maintained its guidance for the full year 2025. While we acknowledge the potential of ARRY as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 10 Cheap Energy Stocks to Buy Now and Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
21 minutes ago
- Yahoo
Regeneron Pharmaceuticals, Inc. (REGN): A Bull Case Theory
We came across a bullish thesis on Regeneron Pharmaceuticals, Inc. (REGN) on Notes From The Beauty Contest's Substack. In this article, we will summarize the bulls' thesis on REGN. Regeneron Pharmaceuticals, Inc. (REGN)'s share was trading at $605.39 as of 29th May. REGN's trailing and forward P/E were 15.39 and 17.39 respectively according to Yahoo Finance. A scientist in a lab conducting research on cell-based therapeutics and biotechnology. Regeneron's latest earnings report was notably weak, with a 3.7% revenue decline and a 14% EPS drop, surprising given the company's history of exceeding market expectations. The primary driver was a steep 26% year-over-year decline in the U.S. Eylea franchise, particularly a 39% drop in 2mg Eylea sales. This was partly due to a co-pay assistance funding gap, which forced many Medicare patients to switch to cheaper alternatives like compounded Avastin, impacting both Regeneron and rival Roche's Vabysmo. Regeneron, having contributed over $400 million last year to charitable foundations supporting co-pay assistance, is now seeking to share this burden, proposing a matching donation program to encourage broader industry support. Another setback was the FDA's Complete Response Letter delaying approval of the Eylea-HD pre-filled syringe, a key product needed to compete with Vabysmo. The delay stemmed from third-party component issues rather than drug efficacy, and management believes resolution could be near. Margins also contracted, with gross margin falling from 89% to 85% due to unspecified inventory write-offs, possibly related to older Eylea 2mg or even leftover REGEN-COV stock. However, the margin pressure appears more tied to one-offs and increased R&D spending than structural issues. On a more positive note, Regeneron's pipeline is broadening meaningfully. Itepekimab, an IL-33 antibody, shows promise as a major respiratory asset with pivotal COPD data upcoming and expanded trials underway. The growing RNAi pipeline, now at nine siRNAs through its Alnylam collaboration, signals Regeneron's potential evolution beyond antibodies into a broader genetic medicine powerhouse. Regeneron Pharmaceuticals, Inc. (REGN) is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 66 hedge fund portfolios held REGN at the end of the first quarter which was 68 in the previous quarter. While we acknowledge the potential of LYFT as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock. Disclosure: None. This article was originally published at Insider Monkey. Sign in to access your portfolio
